Smart Colloidal Systems as Drug Delivery and Therapeutic Modulation Platforms for Renal Cell Carcinoma Authors: Liming Sun, Xinming Zhao, Xiaoting Li, Zhanmeng Zhu, Guangzhen Wu Published: 2026 ABSTRACT AbstractRenal cell carcinoma (RCC) is one of the major malignant tumors of the genitourinary system and remains difficult to treat in advanced or recurrent settings. Although surgery, antiangiogenic targeted therapy, immune checkpoint blockade, mTOR inhibition, and HIF-2α-targeted therapy have improved clinical outcomes, recurrence, therapeutic resistance, heterogeneous tumor exposure, and systemic toxicity continue to restrict long-term efficacy. Smart colloidal systems have attracted attention as drug delivery and therapeutic modulation platforms because their size, surface properties, composition, and responsiveness can be engineered to improve drug stability, tumor accumulation, intracellular delivery, and controlled release. In this review, “smart colloidal systems” refers to functionally engineered colloidal platforms whose design confers therapeutic behavior beyond passive drug encapsulation, including selective tumor- or cell-directed delivery, controlled or stimulus-triggered release or activation, enhanced intracellular delivery, intrinsic carrier-mediated biological effects, and coordinated multimodal therapy. In RCC, these systems have been explored for the delivery of tyrosine kinase inhibitors, immune agonists, checkpoint-regulating nucleic acids, therapeutic genes, siRNAs, ferroptosis-inducing agents, photosensitizers, sonosensitizers, and combination regimens. This review summarizes recent progress in smart colloidal systems for RCC therapy from a treatment-modality perspective, including targeted therapy, immunotherapy, gene and RNA therapy, metabolic and ferroptosis-based therapy, externally triggered therapy, and combination treatment. However, most RCC-directed smart colloidal systems remain at the preclinical stage. Toxicity, renal safety, immune compatibility, biodistribution, manufacturing feasibility, and clinical translation are also discussed. By linking the delivered cargo, colloidal platform, biological rationale, and antitumor strategy, this review aims to clarify the potential value and limitations of smart colloidal systems in RCC treatment.Keywords: clear cell renal cell carcinoma, smart colloidal systems, nanoparticles, drug delivery, immunotherapy, RNA therapy Introduction Renal cancer represents one of the major malignant neoplasms of the genitourinary system and continues to impose a substantial global disease burden. According to GLOBOCAN 2022 estimates, kidney cancer accounted for more than 430,000 new cases and over 150,000 deaths worldwide.1 Renal cell carcinoma (RCC) constitutes the predominant pathological type of kidney cancer, among which clear cell renal cell carcinoma (ccRCC) is the most common histological subtype.2 The clinical management of RCC is strongly influenced by disease stage, histological subtype, tumor biology, and patient-related factors. For localized disease, partial or radical nephrectomy remains the principal curative approach, whereas systemic treatment is required for advanced or metastatic RCC.2,3 The therapeutic landscape of advanced RCC has changed substantially over the past two decades. VEGF/VEGFR-targeted tyrosine kinase inhibitors, mTOR inhibitors, immune checkpoint inhibitors, and HIF-2α-targeted therapy have expanded the available systemic treatment options.3,4 In particular, immune checkpoint inhibitor-based regimens, including nivolumab plus ipilimumab and pembrolizumab plus axitinib, have demonstrated clinical benefit in advanced RCC and have become important components of first-line treatment strategies.5,6 Nevertheless, current therapeutic approaches remain constrained by recurrence after local treatment, primary or acquired resistance to systemic therapy, treatment-related toxicity, heterogeneous intratumoral drug exposure, and the absence of robust biomarkers capable of reliably guiding treatment selection in individual patients.3,4,7 These limitations indicate that improving therapeutic efficacy in RCC depends not only on identifying active drugs, but also on optimizing how, where, and when these agents act within the tumor and its microenvironment. Recent clinical guidelines further emphasize that systemic treatment for advanced clear cell RCC should be selected according to prognostic risk, prior therapy, comorbidity, and the anticipated balance between efficacy and toxicity.8,9 Several pivotal trials have shaped this approach, including adjuvant pembrolizumab after nephrectomy in high-risk RCC, nivolumab plus cabozantinib, pembrolizumab plus axitinib, avelumab plus axitinib, nivolumab versus everolimus, lenvatinib plus pembrolizumab, and belzutifan versus everolimus after prior immune checkpoint and antiangiogenic therapy.10–16 These clinical advances provide the therapeutic background for evaluating whether colloidal systems can improve delivery, reduce systemic exposure, or rationally combine agents that are already active in RCC. In recent years, smart colloidal systems have achieved encouraging results in the treatment of renal cancer (Table 1). Table 1Representative Smart Colloidal Systems for RCC TherapyTherapeutic ModalityRepresentative PlatformPayload or Functional ComponentMain Antitumor StrategyReferencesTargeted therapySorafenib-loaded PLGA nanoparticles and DPPC liposomesSorafenibImprove formulation performance and RCC cell killing at lower drug exposure[17]Targeted therapySunitinib-loaded green tea-based micellar nanocomplexSunitinibUse PEG-EGCG carrier-drug synergy to enhance antiangiogenesis and reduce normal renal toxicity[18]Targeted therapyTumor-supplying artery Liposome@SunitinibSunitinibIncrease renal tumor retention through anatomical delivery and colloidal trapping[19]Targeted therapyCabozantinib-loaded PLGA nanoparticlesCabozantinibProvide sustained antimetastatic exposure after nephrectomy[20]ImmunotherapySTING agonist-loaded lipid nanoparticlesSTING agonistActivate innate antitumor immunity and reduce RCC lung metastasis[21]ImmunotherapyNGR-modified liposomesAxitinib and PD-L1 siRNASynchronize vascular modulation with checkpoint gene silencing[22]Gene/RNA therapyVitronectin-enriched lipid nanoparticlesmRNA or HIF2α siRNAUse endogenous protein-corona targeting to improve ccRCC delivery[23]Gene/RNA therapyAS1411-functionalized LNPssiRNA against circPDHK1Silence a circRNA-encoded oncogenic peptide axis[24]Gene/RNA therapyHA-modified PLGA nanoparticlesCircsnx6 siRNATarget CD44-positive resistant RCC cells and reverse sunitinib resistance[25]Metabolic/ferroptosis therapyMIL-101(Fe)@RSL3 nanodrugIron-based MOF and RSL3Trigger cascade ferroptosis through iron release and GPX4 inhibition[26]Externally triggered therapyThermosensitive liposomes plus focused ultrasoundSorafenibAchieve ultrasound-triggered localized TKI release[27]Externally triggered therapyAPm/Ce6/HIF nanoparticles plus ultrasoundChlorin e6 and belzutifanCombine sonodynamic therapy, HIF-2α inhibition, and immunotherapy sensitization[28]Combination therapyCRLX101/NLG207 plus bevacizumabCamptothecin nanoparticle-drug conjugate plus anti-VEGF therapyClinical-stage nanodrug and antiangiogenic combination with mixed translational results[29,30] Representative Smart Colloidal Systems for RCC Therapy Smart colloidal systems have therefore attracted increasing attention as drug delivery and therapeutic modulation platforms. In this review, “smart colloidal systems” are defined by function rather than by material composition alone. Specifically, we consider a colloidal platform to be “smart” when its engineered design confers a therapeutically relevant behavior that is selective, responsive, programmable, biologically active, or coordinative in relation to a defined RCC-specific biological feature or treatment requirement. Such functions include active or endogenous targeting, microenvironment- or externally triggered activation and release, programmed intracellular delivery, carrier-mediated modulation of tumor biology, and spatial or temporal coordination of complementary therapeutic mechanisms. By contrast, nanoscale encapsulation, solubility enhancement, or passive accumulation alone is not considered sufficient to define a system as smart. Compared with conventional formulations, colloidal nanomedicines can modify the pharmacological behavior of therapeutic agents by improving drug stability, solubility, circulation behavior, biodistribution, tumor accumulation, and intracellular delivery.31,32 More importantly, stimuli-responsive colloidal systems can be engineered to release or activate their cargos in response to endogenous pathological cues, including acidic pH, redox gradients, enzyme activity, hypoxia, and reactive oxygen species, or exogenous triggers, such as light, ultrasound, magnetic fields, and temperature changes.32,33 These properties provide a technical basis for controlled delivery, site-selective activation, and multimodal therapeutic integration. At this stage, RCC-focused nanomedicine research has expanded from nonspecific drug encapsulation toward tumor imaging, theranostic design, renal-oriented biodistribution control, nucleic acid delivery, and multimodal treatment.34,35 However, the clinical performance of a colloidal formulation is determined by multiple biological barriers, including circulation stability, protein corona formation, vascular extravasation, interstitial penetration, cellular uptake, endosomal escape, and renal or hepatic clearance.36–40 Liposomes and lipid nanoparticles remain among the most widely studied platforms, particularly for small-molecule and RNA delivery, because their composition can be modified to regulate cargo loading, membrane fusion, immune compatibility, and intracellular release.41–45 The application of smart colloidal systems to RCC is particularly relevant because several biological and anatomical characteristics of RCC correspond to the functions of these platforms. RCC is commonly associated with aberrant angiogenic signaling, hypoxia-related adaptation, immune microenvironment remodeling, metabolic reprogramming, and therapeutic resistance.2–4 These features create opportunities for vascular targeting, hypoxia-responsive delivery, immune modulation, nucleic acid delivery, ferroptosis-oriented intervention, and externally triggered treatment. Therefore, smart colloidal systems should not be considered merely as passive carriers. Rather, they may serve as functional therapeutic systems that coordinate tumor-oriented delivery, controlled release, intracellular trafficking, local activation, and combination therapy. This review examines smart colloidal systems for RCC through treatment modality rather than material taxonomy. By linking therapeutic cargo, colloidal architecture, RCC biology, and translational constraints, it distinguishes ordinary nanoscale drug loading from systems that add tumor targeting, stimulus responsiveness, spatiotemporal activation, immune remodeling, or coordinated combination therapy. The following sections therefore consider targeted therapy, immunotherapy, gene and RNA therapy, metabolic and ferroptosis-based therapy, externally triggered therapy, and combination treatment, followed by toxicity and clinical translation. This organization is intended to clarify where smart colloids provide genuine therapeutic modulation and where additional evidence is still needed before clinical adoption (Figure 1). Overview of smart colloidal systems for renal cell carcinoma therapy. The schematic summarizes the major functions, representative platforms, endogenous and exogenous triggers, therapeutic modalities, and potential therapeutic outcomes of smart colloidal systems in RCC. Representative platforms include liposomes, lipid nanoparticles, polymeric nanoparticles, extracellular vesicle-like carriers, and metal-organic framework nanoparticles. Their functions include improving drug stability and tumor accumulation, enabling controlled or stimuli-responsive release and intracellular delivery, and modulating the tumor microenvironment. Endogenous and exogenous triggers include acidic pH, redox/ROS conditions, hypoxia, enzymes, ultrasound, and NIR light. These systems have been investigated in targeted therapy, immunotherapy, gene/RNA therapy, metabolic and ferroptosis-based therapy, externally triggered therapy, and combination treatment. The potential therapeutic objectives include enhanced antitumor efficacy, resistance modulation, improved tumor selectivity, reduced systemic toxicity, and greater translational potential. Abbreviations: RCC, renal cell carcinoma; TKI, tyrosine kinase inhibitor; HIF-2α, hypoxia-inducible factor-2α; STING, stimulator of interferon genes; PD-L1, programmed death-ligand 1; siRNA, small interfering RNA; mRNA, messenger RNA; circRNA, circular RNA; GPX4, glutathione peroxidase 4; ROS, reactive oxygen species; NIR, near-infrared; RNAi, RNA interference; SDT, sonodynamic therapy; MMPs, matrix metalloproteinases. Fe2⁺ indicates ferrous iron, and the downward arrow next to O2 indicates reduced oxygen availability/hypoxia. PubMed was searched for relevant English-language publications from database inception through August 6, 2026. Search terms combined “renal cell carcinoma,” “clear cell renal cell carcinoma,” or “kidney cancer” with terms related to smart colloidal systems, their functional characteristics, and the therapeutic modalities covered in this review, including “smart colloidal systems,” nanoparticles, liposomes, lipid nanoparticles, micelles, targeted delivery, stimuli-responsive delivery, controlled release, gene/RNA delivery, immunotherapy, ferroptosis, and externally triggered therapy. Reference lists of relevant articles were screened to identify additional studies. The FDA, EMA, and MHLW websites were also searched for applicable regulatory documents. The Role of Smart Colloidal Systems in Targeted Therapy and the Delivery of Targeted Agents Targeted therapy in RCC is biologically anchored in aberrant angiogenic signaling, VHL/HIF-driven adaptation, VEGF/VEGFR-dependent angiogenesis, and compensatory survival pathways that sustain tumor growth under therapeutic pressure.46,47 VEGF/VEGFR TKIs, including sunitinib, sorafenib, pazopanib, cabozantinib, and lenvatinib-based regimens, have improved outcomes in advanced RCC, whereas HIF-2α inhibitors have expanded the molecularly targeted treatment landscape.48–50 However, durable benefit is limited by systemic toxicity, heterogeneous intratumoral exposure, postoperative recurrence, hypoxia-driven escape, MET/AXL activation, altered lysosomal drug handling, autophagy-associated adaptation, and other resistance programs.51–55 Smart colloidal systems are therefore relevant not simply as drug containers, but as platforms that can reshape local pharmacokinetics, prolong tumor retention, support controlled release, and couple targeted inhibition with resistance-modulating functions. Smart Delivery Platforms for Targeted Agents A primary role of smart colloidal systems in RCC targeted therapy is to improve how targeted agents reach and remain in tumor tissue. Conventional TKIs are generally administered orally or intravenously, which leads to systemic exposure rather than tumor-confined action. Nanoscale colloidal carriers can modify drug solubility, pharmacokinetics, biodistribution, tumor accumulation, and release profiles through liposomal encapsulation, polymeric matrices, PEGylation, active targeting ligands, and size-dependent tumor retention.38,45,56 Early RCC-related formulation studies mainly focused on improving the delivery of poorly soluble TKIs. Liu et al compared sorafenib-loaded PLGA nanoparticles and DPPC liposomes in RCC cells.17 This study was built on the broader principle that polymeric nanoparticles and liposomes can improve the local availability and intracellular exposure of hydrophobic anticancer agents.17,38,45,56 Compared with free sorafenib, the colloidal formulations produced improved RCC cell killing at lower drug exposure.17 Although this system did not contain a strong stimulus-responsive element, it established an important delivery premise: TKIs can be reformulated into biocompatible colloids to improve drug availability and antitumor performance. Active vascular targeting extends this delivery logic toward the angiogenic endothelium. Tumor angiogenesis is driven not only by VEGF/VEGFR signaling but also by endothelial adhesion receptors such as integrin αVβ3, which is enriched on activated endothelial cells and tumor vasculature. The interaction between αVβ3 and VEGFR2 can reinforce angiogenic signaling, providing a mechanistic basis for targeting both pathways simultaneously.57,58 Based on this logic, Bianchini et al developed cAmpRGD-decorated sunitinib liposomes as integrated antiangiogenic delivery platforms.59 Sunitinib blocks VEGFR/PDGFR-related signaling, whereas cAmpRGD promotes αVβ3-directed binding and internalization. The design therefore combines ligand-guided vascular localization with pharmacological blockade of angiogenic signaling. More delivery systems have recently been evaluated in RCC. Adapting a PEG-EGCG micellar platform previously used with other anticancer cargos, Yongvongsoontorn et al formulated the sunitinib-loaded micellar nanocomplex SU-MNC and evaluated it in human RCC xenografts. This system should be distinguished from a conventional liposomal formulation. Its functional rationale is carrier-drug synergy: PEG-EGCG is not merely an inert excipient, but contributes to antiangiogenic activity, while micellar complexation improves the presentation of sunitinib. In RCC xenograft models, SU-MNC showed stronger antiangiogenic, pro-apoptotic, and antiproliferative effects than free sunitinib and reduced toxicity toward normal renal cells.18 Thus, this example illustrates a more advanced principle than improved biodistribution alone: the colloidal carrier can participate in the therapeutic mechanism. Tumor-supplying artery injection of Liposome@Sunitinib is an anatomically RCC-tailored delivery strategy.19 Sunitinib is water-insoluble and conventionally administered orally, which can produce normal-tissue exposure and systemic toxicities. Liposomes can encapsulate hydrophobic drugs and improve local retention through size-dependent trapping and colloidal stability.38 Fu et al combined these properties with a renal tumor delivery route by injecting Liposome@Sunitinib through the tumor-supplying artery in an orthotopic kidney tumor model. This strategy recognizes an RCC-specific delivery problem: renal tumors are highly vascularized, and free drugs delivered through the artery may be rapidly washed out by renal blood flow. By contrast, liposomes can be retained in tumor tissue after arterial perfusion. The study showed that trans-renal arterial administration increased liposome accumulation and prolonged liposome retention in tumor tissue compared with peripheral intravenous delivery, leading to greater sunitinib retention and stronger tumor suppression than peripheral injection or conventional oral sunitinib.19 Its functional rationale is therefore anatomical and pharmacokinetic rather than chemical: the system uses both colloidal retention and renal tumor vascular access to improve targeted therapy. However, the need for selective arterial access may restrict its use to catheter-based locoregional treatment. Sustained-release polymeric systems are particularly relevant to postoperative or adjuvant settings. Cabozantinib inhibits VEGFR2, MET, and AXL-related signaling, which is relevant because MET/AXL activation contributes to resistance after prolonged VEGF-targeted therapy.48,53 PLGA nanoparticles are biodegradable carriers that can provide controlled release and reduce peak-concentration-related exposure.44,56 Lee et al evaluated cabozantinib-loaded PLGA nanoparticles as a potential adjuvant strategy using Renca-SRLu5-Luc cells and an experimental lung-metastasis model designed to recapitulate postoperative RCC relapse. The formulation reduced lung metastatic burden and prolonged survival.20 The central rationale is to maintain antimetastatic pressure during a vulnerable postoperative interval while avoiding the exposure peaks that often limit systemic TKI therapy. Other delivery designs further broaden the concept of intelligent targeted-agent presentation. For RCC treatment, Zeng et al designed ibuprofen-nanoconjugate micelles with E-selectin targeting to enhance sunitinib therapy by integrating vascular adhesion-related targeting with anti-inflammatory modulation.60 Li et al constructed DNA origami nanotapes for sunitinib adsorption and receptor tyrosine kinase inhibition in 786-O renal clear cell carcinoma cells.61 DNA origami-constructed nanotapes were used for sunitinib adsorption and receptor tyrosine kinase inhibition in renal clear cell carcinoma cells. DNA nanostructures are programmable nanoscale materials whose geometry and surface organization can be engineered with high precision. In this context, DNA nanotapes function as structured drug-presenting platforms: sunitinib is adsorbed onto the DNA surface, allowing prolonged interaction with membrane receptor tyrosine kinases.61,62 Together, these studies show that smart delivery platforms in RCC are evolving from simple encapsulation toward active targeting, anatomical delivery, sustained release, and programmable nanoscale drug presentation. Some targeted-agent formulations also rely on ultrasound, light, or other external physical inputs to achieve localized release or activation. When external physical inputs dominate therapeutic performance, the central value of the colloidal system shifts from conventional payload delivery to spatially and temporally controlled treatment. Resistance-Reversing Smart Colloids in Targeted Therapy A further function of smart colloidal systems is to attenuate resistance to targeted therapy. RCC resistance to VEGF-targeted TKIs includes both primary non-response and adaptive changes that emerge during treatment. Initially sensitive tumors can restore vascular support through VEGF-independent proangiogenic signaling, activate stress-survival pathways, and remodel the immune microenvironment.63,64 In ccRCC, increased IL-8 expression contributed to sunitinib-resistant angiogenesis, whereas IL-8 neutralization resensitized resistant xenografts.65 Sunitinib can also activate PERK-dependent production of IL-6, IL-8, and TNF-α together with NF-κB-mediated survival signaling in RCC cells, showing that treatment-induced stress responses may promote a refractory phenotype.66 Adaptation is not restricted to tumor cells: RCC specimens obtained after antiangiogenic therapy showed increased regulatory T-cell infiltration and PD-L1 expression.67 These findings indicate that RCC resistance is sustained across tumor-cell, vascular, and immune compartments. Resistance-oriented colloidal systems should therefore be evaluated not only by drug loading or tumor accumulation, but also by their capacity to disrupt the compensatory programs that limit response to targeted therapy. Hypoxia-directed nanotherapy addresses a disease niche that is central to ccRCC biology. Clear cell RCC is closely associated with VHL/HIF/VEGF signaling, and antiangiogenic therapy can intensify hypoxic pressure. Hypoxia can promote angiogenic escape, metabolic adaptation, macrophage recruitment, immune suppression, and drug resistance.63,64 Alsaab et al developed an RCC-tailored CA IX-directed nanoparticle by conjugating the CA IX-binding ligand acetazolamide to the SMA-TPGS carrier, thereby delivering the apoptosis inducer CFM 4.16 into hypoxic RCC regions; the formulation was combined with sorafenib. CA IX targeting exploited the hypoxic tumor core, whereas sorafenib provided antiangiogenic targeted pressure. The combination inhibited p-AKT, promoted caspase-3/7-mediated apoptosis, enhanced tumoricidal M1 macrophage responses, reduced tumorigenic macrophage features, and suppressed everolimus-resistant RCC growth without evident liver or kidney toxicity.68 The study is valuable because it treats hypoxia as an actionable resistant niche rather than a passive barrier to drug delivery. This design benefits from the frequent and relatively homogeneous expression of CA IX in ccRCC. Functional inorganic nanomedicine provides another resistance-reversing strategy. Sunitinib resistance is associated with bypass signaling, including MET/AXL activation and downstream AKT/ERK survival pathways.53 Building on earlier studies demonstrating the antitumor activity of cuprous oxide nanoparticles (CONPs) in cultured tumor cells and melanoma models, Yang et al evaluated these nanoparticles in RCC and showed that they disrupt intracellular copper handling by regulating the copper chaperone proteins ATOX1 and CCS, leading to calcium and ROS accumulation, ER stress, and ER- and mitochondria-dependent apoptosis. In sunitinib-resistant RCC models, these nanoparticles also downregulated AXL, MET, AKT, and ERK and restored sunitinib responsiveness.69 The functional relevance of CONPs is therefore not carrier-based. The nanoparticle itself exploits copper-trafficking vulnerability and resistance-associated signaling to alter the biological state of TKI-resistant RCC. Colloidal platforms may also sensitize RCC cells to targeted therapy by introducing biological modifiers. Sorafenib can suppress angiogenic signaling but may also induce protective autophagy and stemness, which reduce its antitumor efficacy.70 Adapting an H1/pHGFK1 gene-delivery system previously evaluated in glioblastoma, Gao et al PEGylated the H1 carrier to generate PH1/pHGFK1 nanoparticles for systemic delivery of the antiangiogenic HGFK1 plasmid in RCC and combined them with sorafenib. HGFK1 enhanced sorafenib-induced apoptosis and cell-cycle arrest while reducing sorafenib-induced autophagy and stemness through blockade of NF-κB signaling.70 In this setting, the nanoparticle does not simply raise intratumoral drug concentration; it adds an antiangiogenic gene module that changes how tumor cells respond to the targeted agent. Taken together, RCC targeted-agent colloids now span TKI reformulation, vascular targeting, anatomical delivery, sustained release, triggered release, and resistance modulation. The Role of Smart Colloidal Systems in Immunotherapy Immunotherapy has reshaped the treatment landscape of advanced RCC. Immune checkpoint inhibitors (ICIs), particularly PD-1/PD-L1- and CTLA-4-targeted antibodies, have produced durable benefit in a subset of patients, and ICI-based combinations are now important first-line regimens for advanced RCC.5,11,14,15 Nevertheless, clinical responses remain heterogeneous because RCC immunity is regulated by more than checkpoint expression alone. The RCC tumor microenvironment contains exhausted and dysfunctional T cell states, tumor-associated macrophages, myeloid suppressive populations, regulatory T cells, abnormal vasculature, hypoxia-associated suppression, and variable antigen-presentation programs.71–76 Abnormal tumor vasculature can further restrict immune-cell access and reinforce immunosuppression, providing a mechanistic bridge between vascular modulation and immune checkpoint therapy.77 These features provide a mechanistic basis for smart colloids that deliver immune agonists, locally silence checkpoint pathways, reprogram macrophages, normalize vascular barriers, and convert immunologically restricted tumor regions into more responsive immune niches. This immune context also explains why immune-oriented colloids should be evaluated by more than drug loading or tumor accumulation. A useful platform should increase the probability that innate activation, antigen presentation, lymphocyte infiltration, checkpoint relief, and myeloid remodeling occur in the same spatial compartment. RCC single-cell and immune atlas studies support this logic by showing that response to PD-1 blockade is shaped by both tumor-intrinsic programs and the organization of lymphoid and myeloid compartments.73,75,76 Innate Immune-Activating Colloids One strategy is to use smart colloidal systems to activate innate immunity. Effective antitumor immunity often requires immune priming before T cell-mediated killing can occur. Type I interferon signaling in dendritic cells is important for antitumor T cell priming, and the cGAS-STING pathway is a central mechanism by which host antigen-presenting cells sense tumor-derived cytosolic DNA and initiate innate antitumor immunity.78 However, free STING agonists are limited by poor pharmacokinetics, rapid systemic diffusion, insufficient intracellular delivery, and potential systemic inflammation. Nanocarriers can address these limitations by packaging STING agonists, promoting cell uptake, increasing intracellular delivery, and controlling the site and intensity of innate immune activation.79–82 STING agonist-loaded lipid nanoparticles illustrate the application of an established cancer immunotherapy platform in RCC. Based on earlier evidence that this formulation activated NK cells and suppressed anti-PD-1-resistant B16-F10 melanoma lung metastasis, Nakamura et al tested the same STING-LNPs in an experimental Renca lung metastasis model. The LNP delivered a STING agonist into innate immune compartments, stimulated type I interferon-related responses, and activated natural killer cells. In this model, the therapeutic effect appeared to be mainly mediated by NK cell activation rather than by conventional checkpoint-dependent T cell effects, and intravenous STING-LNP treatment markedly reduced lung metastatic colonies.21 STING-LNPs therefore function as immunological amplifiers that convert a weakly responsive metastatic niche into an innate immune-active environment. The broader rationale for this approach is supported by studies showing that cytosolic DNA sensing through STING is required for innate immune recognition of immunogenic tumors and that direct STING activation in the tumor microenvironment can induce systemic antitumor immunity.78,83 Manganese-based colloids represent another form of innate immune activation. Manganese ions can enhance cGAS-STING signaling and promote antitumor immunity, but free manganese lacks tumor-selective control and may cause systemic toxicity. For RCC immunotherapy, Du et al developed hyaluronic acid-coated manganese-polydopamine nanoparticles (PDA-Mn-HA NPs) that bind CD44-expressing RCC cells and tumor-associated macrophages and release manganese ions in a tumor microenvironment-responsive manner. Mechanistically, the platform promoted macrophage M1 polarization through ROS-STING-p38/MAPK signaling and induced ROS-caspase-3/GSDME-dependent pyroptosis in RCC cells through a Fenton-like reaction.84 Its functional rationale is therefore dual-compartment immune remodeling: the same colloidal system targets macrophages and tumor cells to couple innate immune activation with immunogenic tumor-cell injury. Checkpoint-Sensitizing and Gene-Silencing Colloids A second strategy is local immune checkpoint regulation, either to support antibody-based checkpoint blockade or to replace systemic checkpoint inhibition with gene silencing. RCC immunotherapy is now dominated by ICI-based combinations, but systemic antibody therapy does not selectively act in tumor tissue and may induce immune-related adverse events.3,8,9 Tumor cells and tumor endothelial cells can dynamically regulate PD-L1 expression, while abnormal vasculature can restrict cytotoxic T lymphocyte infiltration. Colloidal delivery addresses these linked barriers by protecting checkpoint-regulatory nucleic acids, synchronizing vascular normalization with PD-L1 suppression, and restricting immunomodulation to the tumor microenvironment. The NGR peptide-modified liposomal system co-delivering axitinib and PD-L1 siRNA was designed for RCC. The rationale is based on two linked mechanisms: antiangiogenic therapy can normalize tumor vasculature and improve immune-cell access, while PD-L1 silencing can reduce checkpoint-mediated immune escape. In this system, the NGR motif promoted tumor homing and vascular targeting, axitinib inhibited VEGFR-related angiogenic signaling and increased pericyte coverage and vascular perfusion, and PD-L1 siRNA reduced PD-L1 protein expression in tumor cells. The platform also increased effector T cell and NK cell infiltration while reducing immunosuppressive MDSCs and Tregs, thereby reshaping the immune microenvironment.22 The co-delivery format is important because antiangiogenic effects and checkpoint modulation may otherwise occur at different concentrations, locations, and time windows. By contrast, a liposomal platform can synchronize exposure to a VEGFR-TKI and a checkpoint-silencing nucleic acid within the same tumor region. The therapeutic logic is therefore spatial and temporal coordination of vascular normalization, PD-L1 knockdown, and effector-cell infiltration rather than co-loading alone. Beyond PD-L1 siRNA, broader nanomedicine studies support the use of colloidal systems for immune gene regulation. Lipid and polymeric nanoparticles can protect siRNA or mRNA from degradation, promote cellular uptake, and enable intracellular delivery to immune or tumor cells.85 In cancer immunotherapy, this creates opportunities to silence PD-L1, IDO1, TGF-β-related mediators, or myeloid suppressive programs locally rather than systemically. For RCC, this direction remains early, but it is conceptually important because immune resistance is often mediated by multiple suppressive signals rather than by PD-L1 alone. Immune Microenvironment-Remodeling and Multimodal Colloids A third strategy is to remodel the RCC tumor immune microenvironment. RCC is immunologically active, but immune infiltration does not always predict effective tumor control. Single-cell studies have shown that ICI exposure remodels RCC tumor and immune compartments, and that response is shaped by interactions among tumor-cell programs, cytotoxic and exhausted T-cell states, and myeloid populations.71,73 Therefore, smart colloidal systems should not only deliver immune agonists; they should also modify suppressive microenvironmental features such as hypoxia, abnormal vasculature, macrophage polarization, and therapy-induced immune escape. Hypoxia, abnormal vasculature, and myeloid remodeling are closely connected in RCC. These non-lymphoid components can restrict immune-cell infiltration, reinforce suppressive macrophage states, and reduce sensitivity to checkpoint blockade. Immune-oriented colloidal systems may therefore benefit from designs that reshape the stromal and myeloid context, not only from direct delivery of immune agonists or checkpoint-regulating nucleic acids. Externally activated immunomodulation offers another route to convert local tumor injury into immune-relevant stress. In deep renal tumors, physical activation may be useful when it couples local cytotoxicity with hypoxia modulation, autophagy-related stress, antigen release, or improved immune recognition. This principle is especially relevant for sonodynamic and photodynamic colloids, where spatially confined activation may reduce systemic immune toxicity while increasing local immunogenic pressure. Nanovaccine strategies also provide conceptual support for future RCC immunotherapy. Effective cancer vaccines require coordinated delivery of antigen and adjuvant to antigen-presenting cells, followed by dendritic cell maturation, antigen cross-presentation, and T cell priming. Polymeric STING-activating nanovaccines and dendritic cell-targeted nanovaccine systems have shown that nanoparticles can coordinate antigen delivery with innate stimulation and improve cytotoxic T cell responses.79,86 Although RCC-specific nanovaccine studies remain limited, recent personalized neoantigen vaccine data in kidney cancer support the feasibility of inducing antitumor T cell responses against renal cancer antigens.87 Smart colloidal vaccine systems could potentially strengthen this approach by improving antigen stability, lymph node delivery, dendritic cell uptake, and co-delivery of adjuvants. Overall, immune microenvironment remodeling colloids are of high value when performing multiple functions. The strong platforms will not merely deliver an antibody, cytokine, or adjuvant; they will coordinate innate immune activation, antigen presentation, vascular normalization, checkpoint suppression, and stromal remodeling. For RCC, this is particularly important because immunotherapy resistance often reflects a network-level failure involving tumor cells, endothelial cells, macrophages, dendritic cells, and exhausted lymphocytes rather than a single immune checkpoint. The Role of Smart Colloidal Systems in Gene and RNA Therapy Gene and RNA therapy provides a distinctive therapeutic strategy for RCC, particularly ccRCC, because it can regulate genetic, transcriptomic, and non-coding RNA programs that are difficult to control with conventional small-molecule drugs or monoclonal antibodies. ccRCC is shaped by VHL inactivation, HIF pathway activation, angiogenic reprogramming, PI3K/AKT/mTOR signaling, metabolic adaptation, and dysregulated non-coding RNA networks.88–90 These molecular features create therapeutic entry points for restoring tumor-suppressive or antiangiogenic gene function, silencing oncogenic or resistance-associated transcripts, inhibiting HIF2α expression, and targeting circRNA-driven regulatory axes. The main barrier is delivery. Naked plasmid DNA, mRNA, and siRNA are vulnerable to enzymatic degradation, have poor membrane permeability, undergo rapid clearance, and require efficient intracellular trafficking before they can function. Plasmid DNA must be protected, internalized, and expressed; mRNA must reach the cytoplasm and be translated efficiently; and siRNA must escape endosomes and enter the RNA-induced silencing complex.91,92 Smart colloidal systems are therefore central to RCC gene and RNA therapy because they can combine nuclease protection, tumor accumulation, receptor-mediated uptake, endosomal escape, intracellular release, and active or endogenous targeting strategies.93–96 (Figure 2) Smart colloidal systems for gene and RNA therapy in renal cell carcinoma. (A) mRNA/plasmid delivery using lipid nanoparticles or polymeric nanoparticles. Colloidal carriers facilitate tumor accumulation, cellular uptake, and intracellular delivery of nucleic acids, enabling mRNA translation or plasmid-mediated therapeutic protein expression. (B) Vitronectin-enriched LNPs for HIF-2α siRNA delivery. The vitronectin-associated protein Corona promotes targeting of αVβ3 integrin-expressing ccRCC cells, followed by intracellular siRNA delivery, HIF-2α mRNA silencing, and reduced HIF-2α expression. (C) Representative circRNA-targeted strategies include AS1411-functionalized LNPs carrying siRNA against circPDHK1 through nucleolin-mediated targeting and HA-modified PLGA nanoparticles carrying siRNA against circSNX6 through CD44-mediated targeting. Silencing of circPDHK1 suppresses AKT/mTOR signaling, whereas circSNX6 silencing is associated with reversal of sunitinib resistance. (D) Biological self-assembled siRNA delivery uses the liver as an in vivo bioreactor to generate therapeutic siRNAs, which are packaged into secretory small extracellular vesicles and transported through the circulation. The resulting vesicle-associated siRNAs simultaneously target VEGFR2 and mTOR, suppressing angiogenic and survival-related signaling in RCC. Overall, the schematic illustrates the major steps of colloidal gene/RNA therapy, including nanocarrier formation, tumor-directed delivery, cellular uptake and intracellular delivery, and cargo-specific molecular regulation. Abbreviations: RCC, renal cell carcinoma; ccRCC, clear cell renal cell carcinoma; LNP, lipid nanoparticle; mRNA, messenger RNA; siRNA, small interfering RNA; circRNA, circular RNA; HIF-2α, hypoxia-inducible factor-2α; PLGA, poly(lactic-co-glycolic acid); HA, hyaluronic acid; sEV, small extracellular vesicle; VEGFR2, vascular endothelial growth factor receptor 2; mTOR, mechanistic target of rapamycin; AKT, protein kinase B; EPR, enhanced permeability and retention. Downward arrows indicate decreased expression or signaling activity. Smart Colloids for Therapeutic Gene Expression One application of smart colloidal systems in RCC gene therapy is therapeutic gene expression. In this strategy, the colloidal system delivers plasmid DNA or mRNA so that tumor cells or tumor-associated cells produce a therapeutic product. This approach is different from siRNA therapy: instead of silencing a transcript, it introduces or restores a functional genetic program. Early RCC studies used this logic to restore tumor-suppressive or antiangiogenic gene function. VHL plasmid delivery is biologically rational because VHL loss is a defining event in ccRCC and leads to abnormal HIF pathway activation.89 Xu et al compared three previously developed polyethyleneimine-derived nanoparticles as non-viral gene delivery systems for RCC. By chemically modifying PEI, the authors sought to retain DNA condensation and transfection capacity while improving carrier performance. Among the tested materials, folic acid-modified FA-PEAs improved VHL plasmid transfer and reduced tumor volume in OS-RC-2 xenograft models. This study established an early delivery principle for RCC gene therapy: the therapeutic effect depends not only on the selected gene but also on whether the carrier can deliver that gene into tumor-relevant cells.93 Intracellularly responsive lipid carriers provide a more functional design. Extending a previously developed hepatic pDNA-delivery LNP platform to RCC, Akita et al formulated a neutral lipid envelope-type nanoparticle containing the pH-activated, vitamin E-scaffold lipid-like material ssPalmE and evaluated it in OS-RC-2 tumors. The carrier delivered plasmid DNA encoding soluble Flt-1, an antiangiogenic decoy receptor, and suppressed RCC tumor growth. Its functional rationale lies in the carrier chemistry: pH-sensitive tertiary amines and disulfide bonds allow the particle to respond to acidic endosomal conditions and intracellular reductive environments, thereby improving intracellular gene release.94 Recent lipid nanoparticle research has further expanded therapeutic gene delivery from artificial ligand conjugation to endogenous targeting. Vaidya et al adapted the SORT LNP framework to ccRCC by engineering the particles to adsorb circulating plasma vitronectin, the ligand for αVβ3 integrin/vitronectin receptor, which is frequently expressed in ccRCC. By modulating lipid composition, the authors generated vitronectin-enriched LNPs that increased functional mRNA delivery 952-fold in human ccRCC cells in vitro and 42-fold in patient-derived ccRCC tumor fragments orthotopically transplanted in mice.23 This is a representative smart colloidal gene-delivery strategy because the targeting layer is generated in situ after systemic administration. However, delivery depends on αVβ3 expression and may therefore vary among ccRCC tumors. Smart Colloids for RNA Interference-Mediated Gene Silencing A second application is RNA interference-mediated gene silencing. This strategy does not introduce a therapeutic gene; instead, it reduces the expression of a disease-promoting transcript. For ccRCC, HIF-2α is one of the clearest examples. VHL loss stabilizes HIF transcription factors, and HIF-2α drives angiogenesis, metabolic adaptation, tumor growth, and survival.88 Preclinical studies have shown that HIF2α-targeted RNAi can inhibit ccRCC growth, and clinical studies of tumor-directed HIF2α RNAi have provided evidence that RNAi can downregulate HIF2α in advanced ccRCC patients.97–99 These studies support the biological feasibility of RNA interference in RCC, but they also show that therapeutic performance depends on tumor uptake consistency, target engagement, and a manageable therapeutic window. Smart colloids can improve RNA interference therapy by protecting siRNA and directing it toward tumor-relevant cells. The endogenous-targeting LNP study described above also supports this direction because the same vitronectin-enriched LNP logic was explored for HIF2α siRNA delivery. In this setting, the carrier is not a passive vehicle; its physicochemical identity helps determine protein-corona composition, receptor engagement, cellular uptake, and ultimately RNA delivery.23 RNA interference is also attractive for multi-pathway suppression. RCC progression and recurrence are rarely driven by a single pathway, and simultaneous regulation of angiogenesis and growth signaling may be more rational than single-target inhibition.90 Smart RNA systems offer a way to coordinate multiple gene-silencing events within a single therapeutic framework. This point becomes especially relevant for biological self-assembled siRNA systems, where one platform can be designed to regulate more than one transcript. Smart Colloids for Non-Coding RNA-Targeted Therapy A third application is non-coding RNA-targeted therapy. This category separates traditional protein-coding gene silencing from newer RNA targets such as circRNAs, miRNAs, and lncRNAs. CircRNAs are covalently closed, relatively stable, and can regulate cancer progression through miRNA sponging, protein binding, transcriptional regulation, and peptide translation.100 In RCC, circRNAs have been linked to proliferation, migration, metastasis, and drug resistance.24,101,102 Therefore, circRNA-directed siRNA therapy provides a way to interfere with regulatory RNA networks that cannot be directly targeted by conventional drugs. Aptamer-functionalized LNPs extend this strategy to non-coding RNA targets. AS1411 is a DNA aptamer that binds cell-surface nucleolin and has been clinically evaluated in metastatic RCC, which provides disease-relevant support for its use in RCC-targeted delivery.103 Ning et al developed AS1411/LNP-si circPDHK1 as a ccRCC-tailored platform combining the multi-tumor nucleolin-targeting aptamer AS1411 with siRNA against the ccRCC-associated circPDHK1 target in a microfluidics-engineered LNP. The target selection was based on prior evidence that circPDHK1 encodes a 241-amino acid peptide, PDHK1-241aa, which activates the AKT-mTOR pathway and promotes ccRCC progression.101 In vitro and in vivo, AS1411/LNP-si circPDHK1 improved serum stability, circulation time, tumor accumulation, and circPDHK1 silencing. It reduced PDHK1-241aa expression, inhibited AKT and mTOR phosphorylation, suppressed ccRCC proliferation and migration, and reduced tumor growth and hepatic metastasis.24 This platform connects aptamer-guided tumor localization with silencing of a circRNA-encoded oncogenic peptide axis. A second circRNA-targeted strategy focuses on drug resistance. Sunitinib resistance remains a major problem in RCC, and non-coding RNAs can contribute to this adaptive phenotype. CircSNX6 has been reported to promote sunitinib resistance through the circSNX6/miR-1184/GPCPD1/lysophosphatidic acid axis, making circSNX6 a functional resistance target rather than only a biomarker.102 At the delivery level, PLGA nanoparticles provide biodegradable siRNA protection, while hyaluronic acid can target CD44-positive tumor cells. This HA–CD44 logic is relevant because CD44 expression has been associated with ccRCC tumor grade and patient outcome.104 Gao et al tailored a non-RCC-exclusive HA–CD44 delivery strategy to sunitinib-resistant RCC by loading circSNX6 siRNA into HA-modified PLGA nanoparticles. HA-PLGA nanoparticles showed stronger binding to CD44-positive sunitinib-resistant RCC cells than non-targeted formulations. HA-PLGA(circSNX6 siRNA)-NPs improved the sensitivity of 786-O-SUR and ACHN-SUR cells to sunitinib, induced apoptosis, and reversed sunitinib resistance in RCC xenograft models. RNA-seq after circSNX6 knockdown suggested increased apoptosis, mitochondrial changes, and negative regulation of mitochondrial organization.25 The system is best interpreted as resistance-oriented RNA therapy: the carrier enriches siRNA delivery in resistant RCC cells, while the cargo suppresses a circRNA mechanism linked to lysophosphatidic-acid-associated drug resistance. Together, the circPDHK1 and circSNX6 studies show the important value of non-coding RNA-targeted therapy. The first system targets tumor growth and migration by silencing a circRNA-encoded oncogenic peptide axis, whereas the second targets therapeutic resistance by silencing a circRNA-associated resistance pathway. Both examples show that smart colloidal systems can move RNA therapy beyond conventional oncogene silencing toward regulatory RNA network intervention. Biological Self-Assembled RNA Delivery Systems A fourth application is biological self-assembled RNA delivery. This category is conceptually different from synthetic LNPs, PLGA nanoparticles, or ligand-functionalized carriers. Instead of manufacturing a nanoparticle outside the body and then injecting it, biological self-assembly uses endogenous cellular machinery to generate RNA-containing colloidal carriers in vivo.105 Fu et al applied a previously established IVSA-siRNA platform to RCC by designing a genetic circuit that co-expresses VEGFR2- and mTOR-directed siRNAs and reprograms the host liver as a bioreactor. After intravenous administration of DNA plasmid circuits, liver cells used endogenous small RNA processing machinery to generate siRNAs, which were then packaged into secretory small extracellular vesicles and transported through the circulation. The authors constructed circuits co-targeting VEGFR2 and mTOR and evaluated them in two models: an advanced orthotopic ccRCC model and a radical nephrectomy model simulating post-surgical recurrence. IVSA-siRNAs silenced VEGFR2 and mTOR, inhibited tumor growth and lung metastasis, and reduced recurrence after nephrectomy.106 The concept differs from conventional preformulated nanoparticles because the therapeutic carrier is generated biologically in vivo and coordinates multi-gene silencing through endogenous vesicle-associated RNA transport. This strategy links two therapeutic requirements in RCC: coordinated pathway regulation and biologically generated RNA delivery. VEGFR2 and mTOR are both closely related to RCC angiogenesis and tumor growth, and the IVSA-siRNA circuit was designed to silence both targets within one system. Therefore, this platform represents a distinct class of smart colloidal RNA therapy. It uses a genetic circuit and endogenous vesicle-associated RNA transport to implement multi-gene intervention rather than relying on preformulated synthetic particles. Overall, gene and RNA therapy for RCC remains an emerging field, but recent studies define a coherent set of delivery problems and design solutions. Colloidal platforms support therapeutic gene expression, RNA interference, circRNA silencing, resistance reversal, and multi-gene suppression. Their contribution lies in functions that naked nucleic acids cannot provide: tumor-selective accumulation, intracellular responsiveness, endosomal escape, controlled expression or silencing, and integration with established RCC treatment strategies. The Role of Smart Colloidal Systems in Metabolic and Ferroptosis-Based Therapy ccRCC is strongly associated with metabolic reprogramming. VHL inactivation and HIF pathway activation reshape angiogenesis, glycolysis, mitochondrial metabolism, fatty acid handling, lipid storage, and redox homeostasis.89,107 These features are not only descriptive biomarkers of the clear-cell phenotype; they also create exploitable vulnerabilities. Ferroptosis is an iron-dependent form of regulated, non-apoptotic cell death characterized by the accumulation of phospholipid hydroperoxides. Sensitivity to ferroptosis is shaped by the availability of oxidizable polyunsaturated fatty acid-containing membrane lipids and the capacity of GSH–GPX4-dependent antioxidant defenses to remove lipid hydroperoxides. When peroxide generation exceeds this capacity, lipid peroxidation propagates through cellular membranes, causing irreversible loss of membrane integrity and cell death.108–110 Recent studies further show that kidney cancer metabolism involves coordinated changes in glucose utilization, lipid storage, mitochondrial metabolism, amino acid metabolism, redox buffering, and ferroptosis-related lipid peroxide control.90,111–114 This evidence supports treating metabolism- and ferroptosis-oriented colloids as a distinct therapeutic direction rather than a minor extension of conventional cytotoxic delivery. Within this framework, smart colloidal systems are valuable because ferroptosis inducers, redox-active metal ions, GPX4 inhibitors, and lipid peroxide-amplifying agents often require tumor-localized delivery and controlled activation. The central design principle is to increase lipid peroxide pressure, weaken antioxidant defense, alter iron availability, or coordinate these processes within the tumor microenvironment. This section therefore focuses on ferroptosis vulnerability, lipid metabolism-regulating nanoparticles, microenvironment-responsive ferroptosis nanodrugs, and ferroptosis-sensitizing strategies. Metabolic Vulnerabilities as Therapeutic Entry Points The metabolic basis for ferroptosis-based therapy in ccRCC is supported by several mechanistic studies. Miess et al showed that ccRCC cells are highly dependent on glutathione biosynthesis and glutathione peroxidase activity to prevent lipid peroxidation and ferroptotic cell death. In their study, depletion of cystine or disruption of GSH/GPX-related enzymes reduced ccRCC cell viability, while inhibition of GSH synthesis induced ferroptosis that could be rescued by ferroptosis inhibition. The authors further showed that VHL reconstitution shifted ccRCC cells toward oxidative metabolism and reduced ferroptosis sensitivity, whereas inhibition of β-oxidation or mitochondrial ATP synthesis restored ferroptosis sensitivity.113 A related study further connected the clear-cell metabolic phenotype with ferroptosis susceptibility. Zou et al reported that clear-cell carcinomas show a GPX4-dependent state that underlies clear-cell morphology and confers sensitivity to ferroptosis. Their work linked HIF-2α-associated lipid remodeling to enrichment of polyunsaturated lipids and GPX4 dependence, providing a mechanistic bridge between the clear-cell phenotype and ferroptosis vulnerability.114 These findings support an important design principle. ccRCC is not merely a tumor with abnormal lipid storage; it is a tumor that may depend on antioxidant buffering to survive lipid metabolic stress. Therefore, a rational ferroptosis-oriented colloid should do more than deliver a general cytotoxic agent. It should increase lipid peroxide pressure, weaken antioxidant defense, alter iron availability, or combine these mechanisms in a controlled manner. The Hippo pathway also helps explain why ferroptosis sensitivity may vary among RCC cells. Yang et al reported that ferroptosis susceptibility in RCC is influenced by cell density and is regulated by TAZ through the EMP1–NOX4 axis. TAZ activation increased ferroptosis susceptibility, while TAZ removal conferred resistance to ferroptosis. Mechanistically, TAZ regulated EMP1, which in turn affected NOX4, a renal-enriched ROS-generating enzyme involved in lipid ROS accumulation.115 Other RCC studies have also connected ferroptosis regulation with tumor progression and therapeutic vulnerability. KLF2 has been reported to inhibit ccRCC migration and invasion by regulating ferroptosis through GPX4, and ISCA2 inhibition was shown to reduce HIF signaling and induce ferroptosis in ccRCC models.116,117 These studies expand the mechanistic background beyond the GSH/GPX4 axis and suggest that ferroptosis sensitivity is shaped by a broader network involving transcriptional regulation, iron-sulfur cluster biology, HIF activity, and oxidative stress control. Lipid Metabolism-Regulating Colloids One therapeutic direction is to use colloidal materials to regulate lipid metabolism in RCC. This approach is distinct from conventional drug delivery because the colloidal material itself may participate in biological regulation. ACSL4 is particularly relevant in this context because it shapes cellular lipid composition and influences ferroptosis sensitivity by enriching membranes with polyunsaturated fatty acid-containing lipids.110 Building on the reported anticancer activity of zinc oxide nanoparticles across different tumor types, Zhou and Cao evaluated their effects on lipid metabolism in RCC models. They reported that zinc oxide nanoparticles suppressed RCC cell proliferation and viability in vitro and in vivo. Mechanistically, the study linked this effect to upregulation of miR-454-3p and repression of ACSL4, together with reductions in ROS, malondialdehyde, triglyceride, total cholesterol, and lipid droplet accumulation. The authors also reported that ACSL4 was elevated in RCC tumor samples and associated with poor prognosis.118 This study supports a metabolism-regulating interpretation of smart colloids. The nanoparticle is not only a carrier; it acts as a bioactive material that alters a lipid metabolic axis. In the context of RCC, this is important because lipid accumulation and fatty acid metabolism are closely related to tumor adaptation. A colloid capable of reshaping lipid metabolic readouts may therefore provide a therapeutic route that differs from direct kinase inhibition or immune checkpoint blockade. Microenvironment-Responsive Ferroptosis Nanodrugs A second direction is to design nanodrugs that directly amplify ferroptosis. Direct ferroptosis agonists such as RSL3 are mechanistically attractive because GPX4 is a central ferroptosis suppressor, but small-molecule ferroptosis inducers may require improved tumor delivery and controlled activation to achieve stronger tumor-localized effects.109,119 Iron-based nanomaterials are especially relevant because they can supply redox-active iron and promote Fenton reaction-mediated oxidative stress. Ni et al developed MIL-101(Fe)@RSL3 around the PUFA-rich and GPX4-dependent ferroptosis vulnerability of ccRCC. After uptake by 786-O cells, the nanoparticles colocalized with endosomal and lysosomal compartments. In vitro, the release of RSL3 and iron was faster at pH 5.0 than at pH 7.4, supporting acid-responsive degradation within the lysosomal environment. The released iron promoted iron overload and Fenton reaction-mediated oxidative stress, whereas RSL3 inhibited GPX4-mediated lipid peroxide detoxification. In a subcutaneous 786-O xenograft model, intravenously administered MIL-101(Fe)@RSL3 accumulated in tumors and inhibited tumor growth. Tumor Prussian-blue staining and reduced GPX4 expression supported intratumoral iron release and pharmacodynamic activity, whereas serum creatinine, blood urea nitrogen, body weight, and kidney histology showed no obvious short-term toxicity41. The design aligns with the lipid-rich clear-cell phenotype by combining intracellular acid-responsive iron release with GPX4 inhibition, although its efficacy may vary with lysosomal processing and intrinsic ferroptosis sensitivity. Nanoparticle Regulation of Ferroptosis Signaling A third direction is to regulate ferroptosis-associated signaling pathways using bioactive nanoparticles. This direction is conceptually important because ferroptosis is not only a terminal oxidative event; it is shaped by upstream signaling networks, redox enzymes, lipid metabolism, and transcriptional programs.115 In RCC, YAP/TAZ-related signaling is particularly relevant because Hippo pathway effectors have been linked to ferroptosis sensitivity and oxidative stress regulation. Following earlier applications of zinc oxide nanoparticles across several cancer types, Wang et al examined their ferroptosis-related activity in RCC through the miR-27a-3p/YAP axis. In CAKI-1, 786-O, and 769P cells, zinc oxide nanoparticles reduced GPX4 and SLC7A11 expression, increased ROS and Fe2⁺ levels, and inhibited cell survival, invasion, and migration. These effects were linked to induction of miR-27a-3p and downregulation of YAP and were partially reversed by YAP overexpression or miR-27a-3p inhibition. In a subcutaneous CAKI-1 xenograft model, the nanoparticles suppressed tumor growth and altered tumor miR-27a-3p and YAP expression, although ferroptosis was not directly confirmed in vivo.120 This study connects nanoparticle activity with a ferroptosis-related regulatory axis. Its importance lies in the fact that ferroptosis induction is not treated as a nonspecific oxidative effect; instead, it is linked to a defined miRNA–YAP mechanism. When considered together with the TAZ–EMP1–NOX4 study, it suggests that Hippo pathway-related transcriptional programs may be relevant to ferroptosis-based colloidal therapy in RCC. Metabolic and ferroptosis-based smart colloids remain preclinical in RCC. Their development will require evidence that tumor-localized ferroptotic stress can be achieved without nonspecific oxidative injury and remains effective across RCC models with different metabolic and redox states. These requirements will determine whether ferroptosis-based colloids can be integrated with targeted, RNA-based, or immune therapies. The Role of Smart Colloidal Systems in Externally Triggered Therapy Externally triggered therapy is an important component of smart colloidal systems for RCC because it introduces spatial and temporal control into tumor treatment. Unlike conventional systemic therapy, in which exposure is mainly determined by circulation, biodistribution, and passive release, externally activated colloidal systems respond to physical inputs such as ultrasound, near-infrared (NIR) light, magnetic fields, or localized heat. These triggers can induce on-demand drug release, local hyperthermia, ROS generation, acoustic cavitation, photodynamic or sonodynamic activation, vascular disruption, and immunogenic tumor injury.31,33,121,122 This feature is relevant to RCC, where deep anatomical location, rich vascularity, treatment resistance, and preservation of renal function all require precise therapeutic control. Compared with conventional nanocarriers, externally triggered colloids add a physical layer of regulation. The therapeutic agent or functional material can first accumulate in tumor tissue and then be activated at a defined site and time. For RCC, published preclinical evidence mainly concerns ultrasound-triggered delivery and sonodynamic therapy, as well as NIR-triggered photothermal and photodynamic therapy. Magnetic hyperthermia remains a mechanistically relevant but insufficiently validated direction in RCC-specific models.123–127 These strategies are most valuable when integrated with RCC-specific therapeutic logic, including TKI delivery, HIF-2α inhibition, immune checkpoint sensitization, ferroptosis amplification, or vascular modulation.45,50 Ultrasound-Triggered Delivery and Sonodynamic Therapy Ultrasound-triggered systems are attractive for RCC because ultrasound penetrates deeper tissue than light and is already widely used in renal imaging and interventional procedures. In colloidal therapy, ultrasound can promote local drug release, enhance tumor permeability, induce cavitation, or activate sonosensitizers to generate ROS. Therefore, ultrasound-responsive systems are more anatomically suitable for renal tumors than many light-triggered platforms.128 Abshire et al developed sorafenib-loaded thermosensitive liposomes for RCC, using focused ultrasound to localize drug release. The combined treatment produced stronger RCC cell killing than focused ultrasound alone, drug-loaded liposomes alone, non-thermosensitive liposomes with ultrasound, or water-bath heating controls.27 This study shows that the therapeutic effect depended on the matching between the heat-sensitive colloid and the ultrasound trigger. This design provides spatial and temporal control over sorafenib exposure, although its evaluation was limited to an in vitro RCC model and its selectivity depends on precise thermal focusing. Acoustic-responsive microbubbles provide another strategy. Acoustic-responsive microbubbles provide another strategy. Hu et al loaded sunitinib-containing liposomes onto polymer microbubbles and evaluated the formulation in GRC-1 cells and a subcutaneous GRC-1 xenograft model. After intravenous administration, ultrasound was focused on the tumor to rupture the microbubbles. The ultrasound-treated formulation produced greater inhibition of cell survival and xenograft growth than free sunitinib or the corresponding formulation without ultrasound, supporting ultrasound-dependent therapeutic activation. However, intratumoral sunitinib concentration, payload release, biodistribution, and molecular target engagement were not directly measured.129 Sonodynamic therapy further expands the role of ultrasound from a release trigger to a therapeutic activator. Zhu et al designed APm/Ce6/HIF specifically for RCC as a hypoxia-responsive polymeric nanoparticle formed from P-APm and carrying chlorin e6 and the HIF-2α inhibitor belzutifan. The system was designed to address two limitations of sonodynamic therapy in RCC: hypoxia can reduce ROS-dependent treatment efficiency, and SDT-induced autophagy can protect tumor cells. Under ultrasound exposure, APm/Ce6/HIF generated ROS, released belzutifan in the hypoxic tumor microenvironment, inhibited HIF-2α-related signaling, and suppressed protective autophagy. This RCC-tailored combination exploits HIF-2α expression in RCC, although the contribution of belzutifan may vary among tumors, as it inhibited HIF-2α-expressing A498 and 786-O cells but not ACHN cells lacking HIF-2α expression.28 The APm/Ce6/HIF platform also linked sonodynamic therapy with immunotherapy. APm/Ce6/HIF plus ultrasound induced immunogenic cell death, promoted dendritic cell maturation, increased CD8+ T-cell infiltration, increased M1 macrophages while reducing M2 macrophages, and decreased PD-L1 expression. These immune changes were accompanied by enhanced antitumor activity when the platform was combined with anti-PD-1 therapy.28 Thus, this system connects ultrasound activation, hypoxia-responsive drug release, HIF-2α inhibition, autophagy blockade, and experimentally demonstrated immune microenvironment remodeling (Figure 3). Ultrasound-activated smart colloidal systems for multimodal RCC therapy. (A) Schematic representation of the hypoxia-responsive APm/Ce6/HIF nanoparticle containing chlorin e6 (Ce6) and the HIF-2α inhibitor belzutifan. (B) Following tumor accumulation, APm/Ce6/HIF undergoes hypoxia-responsive degradation in the ccRCC microenvironment, resulting in payload release. (C) Ultrasound-triggered therapeutic activation involves two complementary mechanisms: Ce6-mediated ROS generation and sonodynamic therapy and belzutifan release followed by HIF-2α inhibition. (D) APm/Ce6/HIF plus ultrasound induces immunogenic cell death, promotes dendritic cell maturation and CD8+ T-cell infiltration, increases M1 macrophages while reducing M2 macrophages, and decreases PD-L1 expression. (E) These effects are combined with anti-PD-1 therapy to enhance antitumor activity. The lower panel summarizes representative ultrasound-responsive strategies investigated in RCC, including focused ultrasound-triggered sorafenib release from thermosensitive liposomes, sunitinib-loaded ultrasound-responsive microbubbles, and APm/Ce6/HIF combined with anti-PD-1 therapy. Abbreviations: Ce6, chlorin e6; RCC, renal cell carcinoma; ccRCC, clear cell renal cell carcinoma; HIF-2α, hypoxia-inducible factor-2α; ROS, reactive oxygen species; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1. Upward and downward arrows indicate increases and decreases, respectively. NIR-Triggered Photothermal and Photodynamic Therapy NIR-triggered phototherapy mainly includes photothermal therapy (PTT) and photodynamic therapy (PDT). PTT converts light into heat, whereas PDT uses photoactivated sensitizers to generate ROS. Nanoparticle-based platforms can improve the delivery, stability, and tumor localization of photothermal agents or photosensitizers.123,130,131 For RCC, however, light-triggered therapy should be interpreted with anatomical caution because many renal tumors are deep-seated. Its most realistic applications may include locally accessible lesions, superficial metastases, intraoperative treatment, percutaneous optical fiber-assisted therapy, or residual disease after local intervention. Gold nanorod-based systems are early RCC examples of NIR-triggered photothermal therapy. Adapting an HSA–AuNR drug-delivery and photothermal framework previously used with other chemotherapeutic cargos, Callaghan et al developed the sorafenib-loaded HSAP-AuNR-SRF formulation for RCC and tested it in 786-O cells.132 Liu et al subsequently evaluated the same RCC-oriented formulation in bilateral subcutaneous 786-O xenografts; after intratumoral injection and 808-nm irradiation, the combined treatment produced complete tumor necrosis.133 In these systems, gold nanorods served as photothermal transducers, while the TKI component provided molecular inhibition. The value of this design lies in colocalizing pathway inhibition and laser-triggered thermal injury within the same tumor region. Recent RCC studies have focused more on synchronized PDT/PTT systems. Yang et al developed the core-shell TiO2@red phosphorus nanorod formulation in an RCC-focused study and evaluated it in ccRCC models, with treatment localization provided by NIR irradiation. Because pristine TiO2 mainly responds to ultraviolet light, red phosphorus decoration was used to extend optical absorption into the NIR region and enable both local heat generation and ROS production under 808 nm irradiation. In vitro, TiO2@RP nanorods combined with NIR irradiation killed OS-RC-2 and 786-O ccRCC cells while causing relatively lower toxicity to HK-2 normal renal tubular epithelial cells. In vivo, TiO2@RP-25% plus NIR raised local tumor temperature to approximately 48.5 °C, induced tumor apoptosis, and showed no obvious major organ injury.124 P/TiO2 nanoparticles represent a subsequent improvement of this TiO2-based strategy. Song et al synthesized spherical phosphorus-doped TiO2 nanoparticles through vaporization phosphorization. The P/TiO2 nanoparticles extended the photoresponse range to the NIR-II region and generated local heat and multiple oxygen radicals under NIR irradiation. In vitro, P/TiO2 nanoparticles plus NIR damaged 786-O cells and reduced tumor cell survival, while showing better safety toward HK-2 cells than doxorubicin. In vivo, P/TiO2 nanoparticles plus NIR reduced tumor volume by approximately 80% and showed potential anti-metastatic effects by suppressing intratumoral neoangiogenesis.125 Another phosphorus-based platform is the Hittorf’s phosphorus-decorated polymeric carbon nitride heterostructure. Guan et al designed PCN@HP by anchoring Hittorf’s phosphorus nanorods onto polymeric carbon nitride. This heterostructure broadened optical absorption, improved charge separation, generated local heat, and produced ROS under NIR irradiation. In vitro, PCN@HP plus NIR reduced 786-O cell viability while showing limited toxicity toward HK-2 cells. In vivo, PCN@HP plus NIR increased local tumor temperature, reduced tumor burden, and induced stronger tumor damage than control or single-component treatments.126 Taken together, TiO2@RP, P/TiO2, and PCN@HP show that RCC phototherapy is moving from simple light-induced heating toward integrated photoresponsive colloids. These systems use phosphorus-related modification to improve light absorption and synchronize heat generation with ROS production. Their shared strength is dual-mode activation by one external light source; their shared limitation is that light delivery to deep renal tumors remains difficult. Therefore, future NIR-triggered systems should be evaluated not only by photothermal conversion or ROS generation, but also by clinically feasible irradiation routes and renal tissue safety. Magnetic and Field-Responsive Hyperthermia Magnetic hyperthermia is another externally controlled strategy in which magnetic colloids generate heat under an alternating magnetic field. Compared with light-triggered systems, magnetic fields have better tissue penetration and may allow repeated activation.127 In principle, magnetic nanoparticles can also be combined with imaging, drug delivery, and thermosensitive release, making them attractive for deep tumors such as RCC. However, RCC-specific magnetic hyperthermia remains much less developed than ultrasound- and light-triggered therapy. Current evidence is insufficient to treat it as a mature RCC treatment category. Its main challenges include limited tumor-selective accumulation, heterogeneous heat distribution, uncertain long-term clearance, and the need to protect normal renal parenchyma. Therefore, magnetic hyperthermia should be presented as a future-oriented direction in RCC, with emphasis on image-guided activation, quantitative thermal mapping, biodegradable magnetic materials, and combination with targeted or immune therapy. Overall, externally triggered smart colloids are valuable because they add local control to systemic RCC therapy. Ultrasound-triggered systems can improve local drug release and tissue penetration. NIR-triggered systems can synchronize hyperthermia and oxidative damage. Sonodynamic platforms can connect local tumor injury with immune activation. Magnetic systems may provide deeper field-responsive heating in future designs. These functions make externally triggered colloids suitable for combination-oriented RCC treatment rather than isolated physical therapy. The Role of Smart Colloidal Systems in Combination Therapy The current RCC treatment landscape already relies on multimodal intervention, including antiangiogenic targeted therapy, immune checkpoint blockade, HIF-2α inhibition, and local treatment strategies.8,9,13 However, resistance commonly reflects multiple interacting biological layers rather than failure of a single target: abnormal vasculature restricts drug and immune-cell access,77 hypoxia promotes immune suppression and adaptive survival, compensatory signaling sustains proliferation, and RNA or metabolic programs may preserve resistant tumor states. Conventional combination regimens are therefore limited not only by overlapping toxicity, but also by asynchronous pharmacokinetics, nonuniform tumor exposure, and insufficient control over where each therapeutic component acts. Combination therapy represents a higher-order application of smart colloidal systems in RCC. Its value does not simply arise from loading more than one therapeutic agent, but from coordinating complementary mechanisms that are difficult to synchronize with free-drug administration. In cancer therapy, rational combinations are generally used to address pathway redundancy, adaptive resistance, spatial heterogeneity, and treatment-induced escape, while nanomedicine-based combination delivery can further coordinate pharmacokinetics, tumor exposure, and temporal sequence.134–136 In RCC, this principle is particularly relevant because angiogenesis, immune suppression, hypoxia, RNA regulation, and metabolic adaptation often interact within the same tumor ecosystem. Coordinated Vascular, Immune, and Gene-Regulatory Combinations A major combination route coordinates vascular modulation, immune regulation, and gene or RNA intervention within the same tumor context. This approach is particularly relevant to RCC because angiogenesis, immune suppression, TKI resistance, and compensatory signaling are biologically intertwined rather than independent therapeutic problems. Colloidal platforms can align these processes by controlling which cells receive each component, where the components accumulate, and when their biological effects overlap. In gene-enhanced targeted therapy, Gao et al developed PH1/pHGFK1 nanoparticles to deliver HGFK1 and enhance the antitumor effect of sorafenib.70 The pHGFK1 plasmid supplies an antiangiogenic gene module, while sorafenib inhibits angiogenic and oncogenic signaling. By reducing sorafenib-induced autophagy and stemness through NF-κB blockade, this platform modifies the adaptive response to TKI treatment rather than simply adding another cytotoxic pressure. In vascular-immune co-delivery, the NGR-modified liposomal axitinib/PD-L1 siRNA system represents a more spatially coordinated design.22 Axitinib modulates VEGFR-driven angiogenesis and supports vascular normalization, while PD-L1 siRNA reduces tumor immune escape. The liposome therefore functions as an organizing platform that aligns vascular remodeling, checkpoint gene silencing, and effector immune-cell infiltration in the same tumor region. RNA interference can also sensitize RCC cells to other therapeutic stressors. Sakurai et al used a multifunctional envelope-type nanodevice to deliver anti-PLK1 siRNA and combined it with doxorubicin-loaded liposomes in human RCC models. PLK1 silencing enhanced doxorubicin sensitivity, and combined systemic delivery of si-PLK1-loaded YSK-MEND and doxorubicin-loaded liposomes resulted in a measurable delay in OS-RC-2 tumor growth.137 Although conventional chemotherapy is not a central treatment strategy in RCC, this study is useful because the key therapeutic logic is RNA-mediated sensitization rather than chemotherapy alone. Together, these examples indicate that the strongest combination designs are those in which each component addresses a distinct resistance node, such as drug-induced autophagy, stemness, abnormal vasculature, checkpoint-mediated immune escape, or cell-cycle vulnerability. In this setting, the value of smart colloids lies less in multi-cargo loading itself than in coordinating complementary biological effects within the same tumor compartment. Metabolic and Ferroptosis-Based Therapy Combined with Other Modalities Metabolic and ferroptosis-based therapy is likely to be most useful in RCC when combined with other treatment modalities. ccRCC is characterized by metabolic reprogramming, lipid accumulation, redox dependence, and ferroptosis vulnerability. These features provide opportunities to sensitize RCC cells to targeted therapy, immune therapy, or externally triggered oxidative stress. Several studies support the concept that ferroptosis can interact with targeted therapy. Salinomycin has been reported to inhibit SREBP1 and sensitize ccRCC cells to sorafenib-induced ferroptosis, suggesting that metabolic intervention may help overcome sorafenib resistance.138 Although this study is not a colloidal system, it provides a mechanistic rationale for future smart colloids that co-deliver or sequentially activate ferroptosis-sensitizing agents with TKIs. Nanoparticle-based ferroptosis strategies also provide a platform for future combinations. Ferroptosis-inducing nanoparticles can increase iron availability, lipid peroxide generation, GPX4 inhibition, or redox stress, while other modalities such as targeted therapy, phototherapy, or immunotherapy may suppress compensatory survival pathways.119,138 For RCC, this direction should be presented as emerging rather than mature. The key point is that ferroptosis-based colloids should not be isolated from the broader RCC treatment landscape; their most plausible role is to sensitize tumors to established therapies or to amplify oxidative damage induced by photodynamic or sonodynamic treatment. Cytotoxic Payloads as Auxiliary Components in Combination Therapy Although RCC is generally insensitive to conventional chemotherapy, cytotoxic agents may still have a limited role as auxiliary payloads in smart colloidal combination therapy. They should not be presented as an independent major treatment category for RCC, but can be discussed when they are used to support another modality, such as RNA-mediated sensitization, targeted pathway inhibition, or externally triggered tumor damage. For example, liposomal anti-PLK1 siRNA combined with doxorubicin-loaded liposomes demonstrated that RNA interference can improve the efficacy of a cytotoxic agent in RCC models.137 Similarly, tumor-targeted liposomes co-delivering everolimus and vinorelbine combined mTOR inhibition with cytotoxic stress and reduced tumor growth and metastasis in RCC xenografts.139 These studies are useful because they show how cytotoxic payloads can be repositioned as sensitizing or auxiliary modules within multimodal colloidal therapy, rather than as conventional chemotherapy for RCC. Clinical nanodrug experience also provides caution. CRLX101, a nanoparticle-drug conjugate containing camptothecin, was evaluated with bevacizumab in metastatic RCC. An early Phase I–IIa trial showed acceptable safety and preliminary activity, but a randomized Phase II trial did not demonstrate superiority over standard-of-care treatment.29,30 This contrast is important because it shows that rational combination design and early activity do not guarantee clinical benefit. For smart colloidal combination therapy, strong preclinical synergy must be followed by rigorous comparison with active RCC regimens. Toxicity of Smart Colloidal Systems and Challenges for Clinical Translation Although smart colloidal systems offer important therapeutic opportunities for RCC, their clinical translation remains limited. Most RCC-related platforms are still at the preclinical stage, and onl y a small number of nanomedicine or nucleic acid-based systems relevant to RCC have entered clinical evaluation. Translation should therefore be judged not only by antitumor efficacy, but also by renal safety, biodistribution, clearance, immune compatibility, manufacturing reproducibility, target engagement, biomarker-guided patient selection, and demonstrable clinical benefit over established RCC regimens.140–143 This standard is particularly important because increasing colloidal complexity can improve multifunctionality while also increasing formulation variability, toxicity uncertainty, and regulatory burden. Toxicity and RCC-Specific Renal Safety The toxicity of smart colloidal systems is determined by both the loaded therapeutic agent and the carrier itself. Organic platforms, such as liposomes, lipid nanoparticles, polymeric nanoparticles, micelles, and extracellular vesicle-like systems, are generally more biodegradable and clinically familiar, but they may still induce membrane disruption, inflammatory responses, complement activation, or nucleic acid-related innate immune stimulation.144 Inorganic and hybrid systems, including gold, titanium dioxide, zinc oxide, copper-based, iron oxide, phosphorus-based, and metal-organic framework nanoparticles, raise additional concerns regarding long-term tissue retention, metal ion release, ROS overproduction, and incomplete degradation.145 Thus, carrier composition, particle size, surface charge, coating, shape, and degradation behavior should be treated as key safety variables rather than merely formulation parameters. Immune compatibility is another major translational issue. Nanoparticles can activate complement, promote cytokine release, stimulate antigen-presenting cells, or be taken up by macrophages and other mononuclear phagocyte system cells.146,147 These effects may be useful for immunotherapy-oriented platforms, but uncontrolled immune activation may also cause systemic inflammation or off-target immune toxicity. This concern is particularly relevant to RCC because immune checkpoint inhibitors are already widely used, and additional colloid-induced immune activation may alter both therapeutic efficacy and immune-related adverse events. The in vivo fate of colloidal systems further determines both efficacy and safety. After systemic administration, nanoparticles rapidly acquire a biomolecular corona, which can alter circulation time, immune recognition, cellular uptake, and targeting behavior.148 Tumor delivery is also heterogeneous, and a substantial fraction of administered nanoparticles may accumulate in the liver, spleen, or mononuclear phagocyte system rather than in tumor tissue.149,150 Although RCC is often highly vascularized, high vascularity does not necessarily ensure uniform intratumoral nanoparticle penetration. Renal nanomedicine has particular relevance to RCC because the kidney is not only the tumor-bearing organ but also an important site of nanoparticle filtration, tubular uptake, retention, and urinary elimination. Particle size, surface charge, coating, and protein binding can determine whether a formulation crosses the glomerular filtration barrier, remains in the renal parenchyma, or is cleared in urine.151,152 This relationship becomes clinically important after nephrectomy, as patients may enter systemic treatment with reduced nephron mass or pre-existing renal dysfunction. Clinical studies have consistently shown a higher risk of postoperative chronic kidney disease after radical than partial nephrectomy, while renal outcomes are also influenced by baseline kidney function, remaining renal reserve, age, and early postoperative eGFR.153–155 Therefore, renal exposure cannot be evaluated under the assumption that all patients retain two normally functioning kidneys. This anatomy creates both opportunities and risks for colloidal delivery. Evidence from renal nanomedicine indicates that kidney injury can alter both passive and active nanoparticle targeting by changing glomerular filtration barrier permeability and renal cell-surface receptor expression.156 Renal filtration may facilitate the elimination of sufficiently small particles, but filtered materials can also interact with glomerular and tubular compartments. Using renal-clearable gold nanoparticles, Ning et al found that severe cisplatin-induced kidney injury slowed nanoparticle transport in the renal medulla and increased renal retention.157 Huang et al further showed that healthy proximal tubular cells re-eliminated more than 95% of endocytosed gold nanoparticles into urine within one month through an organelle-extrusion mechanism, whereas this process was reduced in cisplatin-injured tubules.158 These findings indicate that nanoparticle clearance measured in healthy animals may not predict its behavior in kidneys with impaired filtration or tubular function. These considerations are directly relevant to RCC-targeted formulations. Vaidya et al demonstrated endogenous accumulation of lipid nanoparticles in kidney tumors,23 showing that the biological characteristics of RCC can support tumor-directed delivery. However, tumor accumulation alone does not establish safety for the remaining normal renal parenchyma, particularly after nephrectomy or in the presence of chronic kidney disease. Future RCC nanomedicine studies should therefore compare exposure in tumor and normal kidney tissue, examine glomerular, tubular, and interstitial localization, monitor renal function and urinary injury markers over time, and determine long-term renal retention and urinary clearance. Where clinically relevant, orthotopic tumor models should be complemented by nephrectomy or renal impairment models. For RCC, an effective formulation must not only reach the tumor but also preserve the function of the remaining kidney. Platform-specific safety should be interpreted according to therapeutic mechanism. Ultrasound-triggered systems require control of acoustic dose, cavitation, heating, and vascular permeability; photothermal or photodynamic systems require attention to off-target heating, light penetration, ROS-related injury, and inorganic material persistence; and metal-based ferroptosis or sonodynamic systems require assessment of degradation, ion release, oxidative stress, and immune activation.28,124,126,129,133 In this context, the absence of obvious acute organ injury is necessary but insufficient for clinical translation (Figure 4). Toxicity and translational considerations for smart colloidal systems. The clinical translation of smart colloidal systems depends on renal safety, immune compatibility, biodistribution, clearance, material persistence, and manufacturing feasibility. Platform-specific risks include complement activation, off-target accumulation, ROS-related injury, ion release, heating damage, and long-term toxicity. Clinical, Manufacturing, and Regulatory Translation Clinical experience also shows that promising delivery concepts do not necessarily produce a clear therapeutic advantage in RCC. The most direct example is CRLX101/NLG207, a cyclodextrin–polymer nanoparticle–drug conjugate developed to improve the solubility, tumor retention, and sustained release of camptothecin. In an early phase I–IIa study, CRLX101 combined with bevacizumab produced partial responses in five of 22 evaluable patients with metastatic RCC. However, the subsequent randomized phase II trial did not demonstrate an improvement over standard therapy. In the clear-cell population, median progression-free survival was 3.7 months with CRLX101 plus bevacizumab and 3.9 months with standard treatment, while the objective response rates were 5% and 14%, respectively. The combination was generally tolerable and produced no new safety signal, suggesting that poor systemic tolerability was unlikely to be the main explanation for the negative result.29,30 A separate biopsy study provided evidence that CRLX101 can reach human tumors and release a biologically active payload. Camptothecin was detected in post-treatment tumor tissue from all nine evaluable patients with gastric, gastroesophageal, or esophageal cancer, and intact nanoparticles were identified in five patients. Changes in topoisomerase I and carbonic anhydrase IX also supported intratumoral pharmacodynamic activity.159 However, these observations were not obtained in RCC. Because the randomized RCC trial did not measure intratumoral nanoparticle deposition, released camptothecin, or downstream target inhibition, it remains unclear whether the lack of clinical benefit resulted from insufficient tumor delivery, suboptimal payload release, limited sensitivity of RCC to camptothecin, or an inadequate therapeutic advantage of the combination itself. CRLX101 therefore shows that improved pharmaceutical properties and tumor localization demonstrated in one tumor setting cannot be assumed to produce superior efficacy in RCC. Because direct clinical evidence for RCC colloidal systems remains limited, related studies of tumor-directed RNA and aptamer therapy also help identify barriers in targeting strategies relevant to colloidal design. ARO-HIF2 is an αvβ3 ligand–conjugated siRNA developed to silence HIF2α in advanced ccRCC.98,99 In the Phase I study, ARO-HIF2 uptake in tumor cells increased with dose, but high concentrations were also detected in stromal cells, including endothelial cells. Reductions in HIF2α were observed in on-treatment biopsies, although the magnitude of knockdown was variable and did not show a clear relationship with dose or tumor-cell αvβ3 expression. Among 26 patients, two achieved partial responses, corresponding to an objective response rate of 7.7%, while the disease control rate was 38.5%.99 Treatment-related neuropathic events occurred in six patients, including one grade 4 peripheral neuropathy. The mechanism remained unresolved: similar neurological toxicity has not been observed with belzutifan, and the original study could not exclude uptake by other cell types or off-target activity of the RNAi trigger. These findings support the feasibility of tumor-directed siRNA therapy in RCC, but also show that cellular distribution, consistency of target engagement, antitumor activity, and neurological safety must be evaluated together. AS1411 provides a complementary lesson for targeting-ligand selection. In a phase II study of the nucleolin-targeted aptamer in metastatic RCC, only one of 35 patients achieved a partial response. This response was marked, with an 84% reduction in tumor burden, and remained progression-free for two years after treatment; however, no additional objective responses were observed. Treatment-related adverse events were limited to mild or moderate events, and systemic exposure in the responding patient was similar to that in nonresponders.103 The trial did not select patients according to tumor nucleolin expression, and archival tumor tissue was not routinely collected, preventing assessment of whether target abundance or tumor uptake explained the heterogeneous response. These findings do not exclude nucleolin as a useful targeting route, but indicate that AS1411-functionalized colloidal systems should be supported by evidence of nucleolin expression, receptor-dependent uptake, and appropriate biomarker-based patient selection. Taken together, these cases reveal different, rather than interchangeable, barriers to clinical translation. For CRLX101, future RCC studies should determine whether the nanoparticle reaches RCC lesions, releases an adequate amount of camptothecin, and produces the expected pharmacodynamic effect before a negative outcome is attributed to the delivery platform. The ARO-HIF2 experience shows that measurable tumor uptake is not sufficient when cellular distribution is broad, target knockdown is variable, and neurological toxicity narrows the therapeutic window. The heterogeneous response to AS1411 further indicates that a targeting ligand should not be advanced without confirming target expression, receptor-dependent uptake, and a biomarker-defined patient population. Limited clinical benefit should therefore be analyzed separately at the levels of delivery, payload release, target engagement, safety, and patient selection rather than being attributed broadly to the carrier or therapeutic target. Multifunctional colloidal systems investigated in RCC may combine multiple cargos, targeting ligands, responsive components, imaging modules, or external triggers, increasing the difficulty of batch control, sterilization, storage, and scale-up.141–143,160 Their manufacturing feasibility therefore depends on whether critical formulation attributes can be reproduced across batches and production scales. A recent review of LNP development identified formulation stability, preparation methods, large-scale production, cost, and regulatory requirements as persistent barriers to clinical translation.161 Nag et al provided a quantitative example by evaluating three batches at each of the 10-, 100-, and 1,000-mL scales, with four measurements per batch. Across these scales, mean particle sizes were 72.00 ± 1.27, 78.82 ± 0.15, and 74.91 ± 0.80 nm; the corresponding PDI values were 0.143 ± 0.025, 0.153 ± 0.011, and 0.120 ± 0.034; and encapsulation efficiencies were 93.33 ± 1.83%, 93.92 ± 2.23%, and 93.44 ± 1.94%, respectively. None of these attributes differed significantly among scales. Although this mRNA-vaccine formulation was not developed for RCC, it provides a quantitative example of the reproducibility expected during LNP scale-up.162 For RCC colloidal systems, core CQAs for evaluating batch-to-batch consistency include particle-size distribution/PDI, physical stability, payload content, the free-versus-associated fraction, and, for drug-loaded formulations, in vitro release behavior measured using a discriminating assay. Actively targeted systems additionally require control of surface charge and ligand density, whereas stimulus-responsive systems require reproducible triggered-release or energy-conversion performance.163,164 These attributes affect dose uniformity, leakage, targeting performance, and renal disposition. Because particle size and surface chemistry influence glomerular filtration, tubular uptake, and renal clearance, normal-kidney exposure and tumor-to-normal-kidney distribution should also be assessed as RCC-relevant nonclinical performance endpoints rather than routine batch-release specifications.151,165 Current regulatory documents are platform-based rather than indication-specific. No guidance dedicated specifically to RCC nanomedicines was identified in the public documents of the FDA, EMA, or MHLW. Applicable documents include the FDA guidance for drug products containing nanomaterials and liposome drug products, the EMA reflection paper on intravenous liposomal products, and the joint MHLW/EMA reflection paper on block-copolymer micelles.163,164,166,167 RCC colloidal products must therefore be evaluated under general drug and platform-specific nanomedicine frameworks, with product-specific justification of their CQAs, manufacturing controls, release behavior, biodistribution, and renal safety. Beyond manufacturing and regulatory requirements, clinical translation also depends on clinically relevant models and appropriate efficacy and safety endpoints. Future RCC studies should also use more clinically relevant models and endpoints. Subcutaneous xenografts cannot fully reproduce renal perfusion, orthotopic tumor growth, post-nephrectomy recurrence, metastatic spread, immune infiltration, or renal parenchymal exposure. Orthotopic, metastatic, immunocompetent, patient-derived, and post-surgical recurrence models should be used more frequently, especially for systems claiming renal tumor targeting, immune remodeling, externally triggered activation, or recurrence prevention. Functional endpoints should also match the platform design: RNA systems should demonstrate intratumoral target knockdown, immune colloids should show tumor-confined immune remodeling, externally triggered systems should report local dosimetry and normal-tissue safety, and postoperative systems should evaluate recurrence and metastasis prevention. Overall, the translation of smart colloidal systems for RCC remains at an early stage. Future development should move beyond proof-of-concept tumor inhibition and place greater emphasis on renal safety, long-term toxicity, immune compatibility, biodistribution, scalable manufacturing, biomarker-guided patient selection, and demonstrable benefit over current standard therapies. The most clinically relevant systems will not necessarily be the most complex, but those that combine disease-specific therapeutic rationale with practical clinical feasibility (Table 2). Table 2Developmental Stage and Translational Status of Representative Smart Colloidal Systems for RCC TherapyRepresentative SystemKey Smart/Functional FeatureDevelopment StageRCC EvaluationMain Translational PointUltrasound-triggered liposomes and microbubbles.27,129Ultrasound-triggered local release and acoustic drug delivery.PreclinicalRCC cells and xenograftsNeeds acoustic dosimetry and normal-tissue safety.Photoresponsive inorganic PTT/PDT systems.124–126,133Light-triggered photothermal/photodynamic activation.PreclinicalRCC preclinical modelsNeeds tissue penetration, clearance, and renal-safety data.Metal/ferroptosis nanodrugs.26Acid-responsive iron release plus GPX4 inhibition.PreclinicalccRCC modelsNeeds tumor-selective ferroptosis and renal-safety validation.APm/Ce6/HIF multimodal SDT platform.28Hypoxia-responsive release plus SDT and HIF-2α inhibition.PreclinicalRCC modelsMultimodal safety and manufacturing remain key barriers.CRLX101/NLG207 + bevacizumab.29,30Self-assembling nanoparticle-drug conjugate; controlled camptothecin release.Clinical: phase I–IIa and randomized phase IIAdvanced/metastatic RCC; NCT01625936, NCT02187302Feasible in humans, but no randomized PFS advantage.Autogene cevumeran (BNT122).168Personalized neoantigen mRNA lipoplex.Clinical: Phase I; active, not recruitingBasket phase I including RCC; NCT03289962Human feasibility shown; RCC-specific efficacy remains unclear.V940 (mRNA-4157) + pembrolizumab.169Personalized neoantigen mRNA-LNP plus PD-1 blockade.Clinical: Phase II; active, not recruitingRCC-specific adjuvant trial; NCT06307431RCC efficacy results are pending. Developmental Stage and Translational Status of Representative Smart Colloidal Systems for RCC Therapy Conclusions Smart colloidal systems in RCC should be considered as functional therapeutic platforms rather than as a single class of nanomaterials. The studies reviewed here show that their main contribution lies in adding functions beyond passive drug encapsulation, including tumor- or cell-directed delivery, controlled or externally triggered activation, intracellular nucleic acid delivery, carrier-mediated biological regulation, and coordination of complementary therapeutic mechanisms. These strategies are relevant to several major problems in RCC treatment, including heterogeneous drug exposure, therapeutic resistance, immune suppression, intracellular delivery barriers, metabolic vulnerability, and the need for spatially controlled combination therapy. However, most of these potential advantages have been demonstrated in preclinical models and should therefore be regarded as therapeutic objectives rather than established clinical benefits. Future studies should place greater emphasis on translational validation. RCC-specific evaluation should quantify drug or nanoparticle distribution in both tumor and normal kidney tissue, confirm payload release and target engagement, and assess renal toxicity, systemic safety, immune compatibility, and long-term material retention. More clinically relevant orthotopic, metastatic, immunocompetent, patient-derived, and post-nephrectomy models should also be used when appropriate. Biomarker-guided patient selection will be important for systems that depend on heterogeneous molecular targets or tumor microenvironmental features. In parallel, scalable manufacturing, reproducible formulation quality, and direct comparison with established RCC therapies should be considered earlier during platform development. Their future impact in RCC will depend on measurable advantages in tumor selectivity, therapeutic coordination, resistance control, safety, and clinical feasibility. With more disciplined platform design, biomarker-guided selection, and translational validation, selected smart colloidal systems may become components of next-generation precision therapy for RCC. Funding Statement This research was supported by the Liaoning Provincial Department of Science and Technology, General Program, 2025 Joint Science and Technology Plan Project (No.5021342), the Dalian Life and Health Guidance Program Project (No. 2024ZDJH01PT068), and the Liaoning Revitalization Talents Program (No.CL001279). Data Sharing Statement Data availability is not applicable to this article as no new data were created or analyzed in this study. Author Contributions All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work. Disclosure The authors declare that they have no competing interests. References Associated Data Data Availability Statement Data availability is not applicable to this article as no new data were created or analyzed in this study.